Author:
Untersmayr Eva,Förster-Waldl Elisabeth,Bonelli Michael,Boztug Kaan,Brunner Patrick M.,Eiwegger Thomas,Eller Kathrin,Göschl Lisa,Grabmeier-Pfistershammer Katharina,Hötzenecker Wolfram,Jordakieva Galateja,Moschen Alexander R.,Pfaller Birgit,Pickl Winfried,Reinisch Walter,Wiedermann Ursula,Klimek Ludger,Bergmann Karl-Christian,Brehler Randolf,Novak Natalija,Merk Hans F.,Rabe Uta,Schlenter Wolfgang W.,Ring Johannes,Wehrmann Wolfgang,Mülleneisen Norbert K.,Wrede Holger,Fuchs Thomas,Jensen-Jarolim Erika
Publisher
Springer Science and Business Media LLC
Reference91 articles.
1. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021;21:e26-e35
2. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 2021;21:83-100
3. Robert-Koch-Institut. Epidemiologisches Bulletin. 2021; www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.pdf?__blob=publicationFile (zuletzt aufgerufen am 15.2.2021)
4. World Health Organisation. Draft landscape and tracker of COVID-19 candidate vaccines. 2021; www.who.int/publications/m/item/draft-landscape-of-covid-19- candidate-vaccines (zuletzt aufgerufen am 16.3.2021)
5. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397:671-81